Aim To improve the knowledge on characteristics, treatment and prognosis in patients with
heart failure (HF) and mid-range ejection fraction discharged after an acute HF episode …

Heart failure (HF) is one of the main causes of morbidity, mortality, and high healthcare
costs. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, reduced …

Aims To describe healthcare resource utilization (HCRU) of patients with heart failure with
preserved (HFpEF), mildly reduced (HFmrEF), and reduced ejection fraction (HFrEF) in …

Aim. To analyze management and outcomes in patients with CHF managed by specialists in
heart failure (HF) or general cardiologists/physicians in real-life clinical practice. Materials …

Aims: To determine the projected benefits of dapagliflozin after an acute heart failure (HF)
event in Spain. Methods: A multicenter and prospective study that included subjects aged 50 …

Objective: The objective of this study was to describe the rates of adverse clinical outcomes,
including all-cause mortality, heart failure (HF) hospitalization, myocardial infarction, and …

Аннотация Цель исследования. Анализ менеджмента и исходов у пациентов с ХСН,
наблюдающихся специалистами по СН или обычными кардиологами/терапевтами в …

Background The addition of hydrochlorothiazide (HCTZ) to furosemide in the CLOROTIC
(Combining Loop with Thiazide Diuretics for Decompensated Heart Failure) trial improved …

Introducción: La falla cardiaca (FC) es un problema de salud pública mundial. En
Latinoamérica, la incidencia es de 199/100.000 personas-año y la prevalencia de≈ 1%. En …

Introduction and objectives There is great interest in better characterizing patients with heart
failure (HF) with preserved ejection fraction (HF-PEF). The objective of this study is to …